Fenton Mary Kay 4

What Happened

• Mary Kay Fenton, Chief Financial Officer of Cullinan Therapeutics (CGEM), disposed of 4,398 shares on Feb 20, 2026. The Form 4 reports an open-market/private sale at $13.62 per share for a total of $59,901. The filing’s footnote says the sale was to cover personal income tax obligations upon the vesting of restricted stock units (RSUs), indicating a tax-covering disposition rather than a new investment.

Key Details

• Transaction date: 2026-02-20
• Price and size: 4,398 shares sold at $13.62 per share; proceeds ≈ $59,901
• Transaction type: Sale (reported as open market or private sale)
• Footnote: F1 — sale to cover personal income tax on RSU vesting
• Filing date: 2026-02-23 (filed within normal Form 4 timing; not flagged as late)
• Shares owned after transaction: not specified in the filing

Context

• This sale appears to be a routine tax-withholding sale tied to RSU vesting. Such sales are common for executives to satisfy tax obligations and do not necessarily signal a change in sentiment about the company. Retail investors typically view purchases as more informative about insider confidence than mandatory or tax-driven sales.